Tamoxifen for breast cancer among hysterectomised women

U. Veronesi, P. Maisonneuve, V. Sacchini, N. Rotmensz, P. Boyle

Research output: Contribution to journalArticle

146 Citations (Scopus)

Abstract

Tamoxifen is a candidate drug for prevention of breast cancer, although findings from trials have not been consistent. In our extended follow-up (median 81.2 months, IQR 66.0-87.2) of the Italian Tamoxifen Trial, this drug did not significantly protect against breast cancer in women at usual or slightly reduced risk of the disease (p=0.215). Use of hormone replacement therapy increased risk of breast cancer, and users of such treatment who were randomly allocated to tamoxifen had a rate of breast cancer that was close to that of never-users. So far, no woman has died from breast cancer in this study. Decisions about introduction of tamoxifen to reduce risk of breast cancer remain important and open questions.

Original languageEnglish
Pages (from-to)1122-1124
Number of pages3
JournalLancet
Volume359
Issue number9312
DOIs
Publication statusPublished - Mar 30 2002

Fingerprint

Tamoxifen
Breast Neoplasms
Hormone Replacement Therapy
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Tamoxifen for breast cancer among hysterectomised women. / Veronesi, U.; Maisonneuve, P.; Sacchini, V.; Rotmensz, N.; Boyle, P.

In: Lancet, Vol. 359, No. 9312, 30.03.2002, p. 1122-1124.

Research output: Contribution to journalArticle

Veronesi, U. ; Maisonneuve, P. ; Sacchini, V. ; Rotmensz, N. ; Boyle, P. / Tamoxifen for breast cancer among hysterectomised women. In: Lancet. 2002 ; Vol. 359, No. 9312. pp. 1122-1124.
@article{ba8187e45a7843069c434c7573531f47,
title = "Tamoxifen for breast cancer among hysterectomised women",
abstract = "Tamoxifen is a candidate drug for prevention of breast cancer, although findings from trials have not been consistent. In our extended follow-up (median 81.2 months, IQR 66.0-87.2) of the Italian Tamoxifen Trial, this drug did not significantly protect against breast cancer in women at usual or slightly reduced risk of the disease (p=0.215). Use of hormone replacement therapy increased risk of breast cancer, and users of such treatment who were randomly allocated to tamoxifen had a rate of breast cancer that was close to that of never-users. So far, no woman has died from breast cancer in this study. Decisions about introduction of tamoxifen to reduce risk of breast cancer remain important and open questions.",
author = "U. Veronesi and P. Maisonneuve and V. Sacchini and N. Rotmensz and P. Boyle",
year = "2002",
month = "3",
day = "30",
doi = "10.1016/S0140-6736(02)08159-X",
language = "English",
volume = "359",
pages = "1122--1124",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Lancet Publishing Group",
number = "9312",

}

TY - JOUR

T1 - Tamoxifen for breast cancer among hysterectomised women

AU - Veronesi, U.

AU - Maisonneuve, P.

AU - Sacchini, V.

AU - Rotmensz, N.

AU - Boyle, P.

PY - 2002/3/30

Y1 - 2002/3/30

N2 - Tamoxifen is a candidate drug for prevention of breast cancer, although findings from trials have not been consistent. In our extended follow-up (median 81.2 months, IQR 66.0-87.2) of the Italian Tamoxifen Trial, this drug did not significantly protect against breast cancer in women at usual or slightly reduced risk of the disease (p=0.215). Use of hormone replacement therapy increased risk of breast cancer, and users of such treatment who were randomly allocated to tamoxifen had a rate of breast cancer that was close to that of never-users. So far, no woman has died from breast cancer in this study. Decisions about introduction of tamoxifen to reduce risk of breast cancer remain important and open questions.

AB - Tamoxifen is a candidate drug for prevention of breast cancer, although findings from trials have not been consistent. In our extended follow-up (median 81.2 months, IQR 66.0-87.2) of the Italian Tamoxifen Trial, this drug did not significantly protect against breast cancer in women at usual or slightly reduced risk of the disease (p=0.215). Use of hormone replacement therapy increased risk of breast cancer, and users of such treatment who were randomly allocated to tamoxifen had a rate of breast cancer that was close to that of never-users. So far, no woman has died from breast cancer in this study. Decisions about introduction of tamoxifen to reduce risk of breast cancer remain important and open questions.

UR - http://www.scopus.com/inward/record.url?scp=0037197090&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037197090&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(02)08159-X

DO - 10.1016/S0140-6736(02)08159-X

M3 - Article

VL - 359

SP - 1122

EP - 1124

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 9312

ER -